Antibody-drug conjugates in acute myeloid leukaemia: more research needed

Lancet Oncol. 2024 Mar;25(3):272-273. doi: 10.1016/S1470-2045(24)00014-7.

Author

Sabine Kayser¹

Affiliation

¹ Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim 68167, Germany; NCT Trial Centre, National Centre of Tumor Diseases, German Cancer Research Center, Heidelberg, Germany. Electronic address: s.kayser@dkfz-heidelberg.de.

PMID: 38423042
DOI: 10.1016/S1470-2045(24)00014-7

No abstract available

MeSH terms

Humans
Immunoconjugates* / adverse effects
Leukemia, Myeloid, Acute* / drug therapy

Substances

Immunoconjugates